Deuterated DMT Composition for Extended Action Without MAO Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing psychedelic compounds like DMT have short durations of action and rapid metabolism, limiting their therapeutic potential, and administration with MAO inhibitors poses dietary restrictions and risks.
Innovation Solution
Development of deuterated DMT compounds with methyl group deuteration to enhance metabolic stability, allowing for extended pharmacokinetics and reduced metabolic clearance, thereby increasing therapeutic potential without the need for MAO inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If deuterated DMT compounds are developed to enhance metabolic stability, then duration of action is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the DMT molecular structure. This isotopic substitution specifically targets the methyl groups at positions 2 and 6 of the indole ring, changing the physical and chemical parameters of the molecule to enhance metabolic stability and prolong duration of action while maintaining the core therapeutic effects of DMT
Solution Approach 2:
The patent creates composite molecular structures by combining deuterated methyl groups with the DMT core structure. The deuterated compounds represent a composite approach where isotopically modified groups are integrated into the parent molecule to achieve enhanced pharmacokinetic properties while retaining the original pharmacological activity
2Reliability
If deuterated DMT compounds are developed to reduce metabolic clearance, then therapeutic potential is improved, but synthesis difficulty increases
Solution Approach 1:
The patent modifies the molecular parameters by introducing deuterium isotopes at specific positions (methyl groups at 2 and 6 positions) of the DMT structure. This parameter change enhances the kinetic isotope effect, reducing metabolic clearance rates and improving therapeutic potential while allowing for controlled synthesis through selective deuteration methods
3Duration of action of moving object
If DMT is administered with MAO inhibitors to extend duration of action, then duration of action is improved, but harmful factors increase due to dietary restrictions and toxic build-up risk
Solution Approach 1:
The patent converts the harmful rapid metabolism of DMT into a benefit by using deuterium substitution to slow down metabolic degradation. The kinetic isotope effect caused by deuterium incorporation reduces the rate at which MAO enzymes can metabolize the compound, thereby extending duration of action without requiring co-administration of MAO inhibitors and their associated dietary restrictions and toxicity risks
Solution Approach 2:
The patent extracts and eliminates the need for MAO inhibitor co-administration by incorporating deuterium directly into the DMT structure. This removes the harmful interactions and dietary restrictions associated with MAO inhibitors while achieving the desired extension of DMT's duration of action through intrinsic metabolic stabilization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterated DMT compounds exhibit increased metabolic stability and prolonged effects, providing a safer and more flexible therapeutic application in psychedelic-assisted psychotherapy for psychiatric and neurological disorders.
Implementation Method 1
The compounds are enriched with deuterium and exhibit a kinetic isotope effect which reduces the metabolic clearance rate of the compounds
Data Source
Figure 1~2
Figure 3A~3B
AI summary
The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I') is also provided.